Suspended NA INTERVENTIONAL 2-arm NCT04226976

Efficacy of a Non-invasive Vestibular System Masking for Improving Outcomes Following Acute Unilateral Vestibulopathy

Efficacy of a Non-invasive Vestibular System Masking for the Abortive Treatment of Vertigo for Patients With Acute Unilateral Vestibulopathy (AUV)

Sponsor: Otolith Labs

Conditions Dizziness Nausea

Interventions Otoband Placebo Device

Updated 6 times since 2020 Last updated: Mar 21, 2022 Started: Jun 1, 2022 Primary completion: May 30, 2024 Completion: Jun 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

COVID-19 general concerns

This NA trial investigates Dizziness and Nausea and is currently suspended. Otolith Labs leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Suspended NA
Jul 2024 — Sep 2024 [monthly]

Suspended NA
Apr 2022 — Jul 2024 [monthly]

Suspended NA
May 2021 — Apr 2022 [monthly]

Suspended NA

Status: Not Yet Recruiting → Suspended
Jan 2021 — May 2021 [monthly]

Not Yet Recruiting NA

▶ Show 1 earlier version

Feb 2020 — Jan 2021 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otolith Labs

Data source: Otolith Labs

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States